Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | lung adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line and as continued maintenance therapy for patients with advanced or metastatic lung adenocarcinoma with CD274 (PD-L1) expression of 1% to 49%, and negative for actionable molecular biomarkers (category 2B) (NCCN.org). | detail... |
| CD274 positive | lung adenocarcinoma | sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with CD274 (PD-L1)-positive (70% tumor cells) metastatic lung adenocarcinoma treated with Keytruda (pembrolizumab) achieved a complete response in multiple brain metastases prior to disease progression in a primary lung lesion after 9 months of treatment, but was subsequently treated with Tepmetko (tepotinib) due to the presence of a MET exon 14 skipping mutation, which resulted in prolonged disease stabilization with no recurrence of brain lesions (PMID: 33335011). | 33335011 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| (33335011) | Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. | Full reference... |